Compare Crispr Therapeutics AG (CRSP) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.6. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRSP | VCIT | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Fixed Income |
52-Week High | $76.78 | $84.82 |
52-Week Low | $44.34 | $81.45 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $81.45, down 0.44% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The fund maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective option for intermediate-duration corporate bond exposure. Recent dividend payments of $0.33-$0.34 per share demonstrate consistent income distribution to investors.
The outlook remains balanced with VCIT offering attractive yield characteristics amid moderate duration risk. Key considerations include interest rate sensitivity and corporate credit quality, with the fund providing diversification across 2,000+ investment-grade bonds. Market sentiment appears cautiously optimistic given the fund's low-cost structure and steady income profile in the current economic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
